Our OncoBEAM tests utilize BEAMing technology (Beads, Emulsions, Amplification, & Magnetics), which is an ultra-sensitive method ideal for ctDNA analysis that employs digital PCR and flow cytometry for reliable detection of rare mutant molecules among an abundance of wildtype molecules.
OncoBEAM is one of the most established technology platforms for liquid biopsy, having been used to advance both clinical validity and utility of plasma-based detection for various clinically-relevant mutations across cancer types such as non-small cell lung cancer, colorectal cancer, and estrogen receptor-positive/ HER2-negative breast cancer.
We offer the following OncoBEAM services to support development of targeted therapies, as well as exploration of novel clinical applications for ctDNA such as molecular monitoring of minimal/measurable residual disease.
If you are interested in specific genes, choose your analytes gene-wise.
| OncoBEAM Tests | No. of Mutations | Mutations Identified and Nucleotide Changes | No. of Amplicons | Assay Validation Status |
|---|---|---|---|---|
| OncoBEAM Breast Cancer Panel | CLIA, GCP, RUO | |||
| AKT1 | 1 | E17K | 1 | |
| g49a | ||||
| ESR1 | 12 | E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, Y537N, Y537S, Y537C, D538G | 3 | |
| g1138c, t1387c, t1601a, c1604a, t1607a, t1607c, t1607g, tc1607-08ag, t1609a, a1610c, a1610g, a1613g | ||||
| PIK3CA | 9 | C420R, E542K, E545G, E545K, Q546K, M1043I, H1047R, H1047L, H1047Y | 3 | |
| t1258c, g1624a, a1634g, g1633a, c1636a, g3129t, a3140g, a3140t, c3139t | ||||
| OncoBEAM Breast Cancer add ons | RUO | |||
| PIK3CA | 9 | R88Q, R93W*, R93Q, K111E, K111N*, G118D, E365K | 3 | |
| g263a, c277g, c277t, g278a, a331g, g333c, g333t, g353a, g1093a | ||||
| OncoBEAM Lung Cancer Panel 1 | CLIA, RUO | |||
| BRAF | 1 | V600E | 1 | |
| t1799a | ||||
| EGFR | 11 | E746_A750del*, E746_S752>V, L747_A750>P, L747_T751del, L747_P753>S, T790M, C797S*, L858R, L861Q | 3 | |
| 2235-49D, 2236-50D, 2237-55Dt, 2239-48Dc, 2240-54D, 2240-57D, c2369t, t2389a, g2390c, t2573g, t2582a | ||||
| KRAS | 10 | G12S, G12R, G12C, G12D, G12A, G12V, G13D, Q61L, Q61H* | 2 | |
| g34a, g34c, g34t, g35a, g35c, g35t, g38a, a182t, a183c, a183t | ||||
| OncoBEAM Lung Cancer add on | RUO | |||
| BRAF | 1 | V600K | 1 | |
| gt1798-99aa | ||||
| OncoBEAM Lung Cancer Panel 2 | GCP, RUO | |||
| ALK | 17 | 1151_1152insT, L1152R, C1156Y, I1171N*, I1171T, I1171S, F1174C, F1174L, V1180L, L1196M, L1198F, G1202R, D1203N, S1206Y, G1269A, R1275Q | 5 | |
| 3453-54inſACG, t3455g, g3467a, t3512a, tc3512-13at, t3512c, t3512g, t3521g, c3522a, g3538c, c3586a, c3592t, g3604a, g3607a, c3617a, g3806c, g3824a | ||||
| ROS1 | 3 | G2032R, Y2092C, L2155S | 2 | |
| g6094a, a6275g, t6464c | ||||
| OncoBEAM Colorectal Cancer Panel 1 | CLIA, GCP, RUO | |||
| BRAF | 1 | V600E | 1 | |
| t1799a | ||||
| KRAS | 15 | G12S, G12R, G12C, G12D, G12A, G12V, G13D, A59T, Q61H*, Q61L, K117N*, A146T, A146V | 4 | |
| g34a, g34c, g34t, g35a, g35c, g35t, g38a, g175a, a183c, a183t, a182t, a351c, a351t, g436a, c437t | ||||
| NRAS | 18 | G12S, G12R, G12C, G12D, G12A, G12V, G13R, G13D, G13V, A59T, Q61H*, Q61R, Q61L, Q61K, K117N*, A146T | 3 | |
| g34a, g34c, g34t, g35a, g35c, g35t, g37c, g38a, g38t, g175a, a183c, a183t, a182t, a182g, c181a, g351c, g351t, g436a | ||||
| OncoBEAM Colorectal Cancer add ons | GCP, RUO | |||
| BRAF | 1 | V600K | 1 | |
| gt1798-99aa | ||||
| HRAS | 2 | Q61R, Q61L | 1 | |
| a182g, a182t | ||||
| OncoBEAM Colorectal Cancer Panel 2 | RUO | |||
| AKT1 | 1 | E17K | 1 | |
| g49a | ||||
| BRAF | 2 | V600E, V600K | 1 | |
| t1799a, gt1798-99aa | ||||
| EGFR | 18 | G719C, G719S, G719A, E746_A750del*, E746_T751>A, E746_S752>V, L747_A750>P*, L747_T751>P, L747_S752del, L747_T751del, L747_P753>S, T790M, C797S*, L858R, L861Q | 4 | |
| g2155t, g2155a, g2156c, 2235-49D, 2236-50D, 2237-51D, 2237-55Dt, 2238-48Dgc, 2239-48Dc, 2239-51Dc, 2239-56D, 2240-54D, 2240-57D, c2369t, t2389a, g2390c, t2573g, t2582a | ||||
| KRAS | 13 | G12S, G12R, G12C, G12D, G12A, G12V, G13D, A59T, Q61H*, Q61L, A146T, A146V | 3 | |
| g34a, g34c, g34t, g35a, g35c, g35t, g38a, g175a, a183c, a183t, a182t, g436a, c437t | ||||
| NRAS | 6 | A59T, Q61H*, Q61K, Q61L, Q61R | 1 | |
| g175a, a183c, a183t, c181a, a182t, a182g | ||||
| PIK3CA | 8 | E542K, E545G, E545K, Q546K, M1043I, H1047R, H1047L, H1047Y | 2 | |
| g1624a, a1634g, g1633a, c1636a, g3129t, a3140g, a3140t, c3139t | ||||
| OncoBEAM Melanoma Panel | GCP, CLIA, RUO | |||
| BRAF | 2 | V600E, V600K | 1 | |
| t1799a, gt1798-99aa | ||||
| NRAS | 5 | Q61H*, Q61R, Q61L, Q61K | 1 | |
| c181a, a182t, a182g, a183t, a183c | ||||
| OncoBEAM AML/Glioma Panel | GCP, RUO | |||
| IDH1 | 5 | R132S, R132G, R132C, R132H, R132L | 1 | |
| c394a, c394g, c394t, g395a, g395t | ||||
| IDH2 | 5 | R140W, R140Q, R140L, R172K, R172M | 2 | |
| c418t, g419a, g419t, g515a, g515t | ||||
| OncoBEAM Prostate Panel | GCP, CLIA, RUO | |||
| AR | 16 | L702H, L702Q***, V716M, W742L, W742C, H875Y, F877L**, T878A, T878S, M896V, M896T | 3 | |
| t2105a, ctc2104-6acc, ctc2104-6acg, ctc2104-6act, ctc2104-6aca, g2148a, g2225t, g2226t, c2623t, t2629c, c2631a, c2631g, a2632g, c2633g, a2686g, t2687c | ||||
| OncoBEAM Pancreatic Cancer Panel | GCP, CLIA, RUO | |||
| KRAS | 10 | G12S, G12R, G12C, G12D, G12A, G12V, G13D, Q61H*, Q61L | 2 | |
| g34a, g34c, g34t, g35a, g35c, g35t, g38a, a183c, a183t, a182t | ||||
Mutations Identified
Nucleotide Change
Information in accordance with Art. 13 GDPR: https://www.sysmex-inostics.com/data
Germany: Sysmex Inostics GmbH, Falkenried 88, D-20251 Hamburg, Germany. +49 (0) 40 – 325907 – 0
United States: Sysmex Inostics, Inc., 1812 Ashland Ave Suite 500, Baltimore, Maryland 21205, USA. +1-855-BEAM-DNA (232-6362)
Japan: Sysmex Corporation, 1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan. +81 78 265-0500
